High field 1H MRS of the hippocampus after donepezil treatment in Alzheimer disease

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 3, 2008, Pages 786-793

  Bartha, Robert ^a,b   Smith, Matthew ^c   Rupsingh, Raul ^a,b   Rylett, Jane ^b   Wells, Jennie L ^b,c   Borrie, Michael J ^b,c  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Alzheimer disease; Dementia; Donepezil; Hippocampus; Magnetic resonance spectroscopy

Indexed keywords

CHOLINE; CREATININE; DONEPEZIL; INOSITOL; N ACETYLASPARTIC ACID;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; MALE; PROTON NUCLEAR MAGNETIC RESONANCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASPARTIC ACID; BRAIN CHEMISTRY; CHOLINE; CHOLINESTERASE INHIBITORS; CREATINE; FEMALE; HIPPOCAMPUS; HUMANS; INDANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PIPERIDINES; PROTONS;

EID: 39749111940     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.12.011     Document Type: Article

References (71)

1. (APA), APA. Diagnostic and statistical manual of mental disorders (1994), American Psychiatric Association (APA), Washington, DC
2. Adalsteinsson E., Sullivan E.V., Kleinhans N., Spielman D.M., and Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 355 (2000) 1696-1697
3. Anthony J.C., LeResche L., Niaz U., von Korff M.R., and Folstein M.F. Limits of the 'Mini-mental state' as a screening test for dementia and delirium among hospital patients. Psychol Med 12 (1982) 397-408
4. Ashburner J., and Friston K. Multimodal image coregistration and partitioning - a unified framework. NeuroImage 6 (1997) 209-217
5. Ballard C.G., Greig N.H., Guillozet-Bongaarts A.L., Enz A., and Darvesh S. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2 (2005) 307-318
6. Bartha R., Drost D.J., Menon R.S., and Williamson P.C. Comparison of the quantification precision of human short echo time (1)H spectroscopy at 1.5 and 4.0 Tesla. Magn Reson Med 44 (2000) 185-192
7. Bartha R., Drost D.J., Menon R.S., and Williamson P.C. Spectroscopic lineshape correction by QUECC: combined QUALITY deconvolution and eddy current correction. Magn Reson Med 44 (2000) 641-645
8. Bartha R., Drost D.J., and Williamson P.C. Factors affecting the quantification of short echo in-vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed 12 (1999) 205-216
9. Baslow M.H. Evidence supporting a role for N-acetyl-l-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Neurochem Int 40 (2002) 295-300
10. Baslow M.H. N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res 28 (2003) 941-953
11. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (2006) CD005593
12. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82 (1991) 239-259
13. Ceravolo R., Volterrani D., Tognoni G., Dell'Agnello G., Manca G., Kiferle L., et al. Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer disease. Clin Neuropharmacol 27 (2004) 166-170
14. Chen J.G., Charles H.C., Barboriak D.P., and Doraiswamy P.M. Magnetic resonance spectroscopy in Alzheimer's disease: focus on N-acetylaspartate. Acta Neurol Scand, Suppl 176 (2000) 20-26
15. 1H-MRS using water as an internal standard. Magn Reson Imaging 11 (1993) 107-118
16. Clark J.B. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 20 (1998) 271-276
17. David J.P., Ghozali F., Fallet-Bianco C., Wattez A., Delaine S., Boniface B., et al. Glial reaction in the hippocampal formation is highly correlated with aging in human brain. Neurosci Lett 235 (1997) 53-56
18. de Graaf A.A., van Dijk J.E., and Bovee W.M. QUALITY: quantification improvement by converting lineshapes to the Lorentzian type. Magn Reson Med 13 (1990) 343-357
19. De Santi S., de Leon M.J., Rusinek H., Convit A., Tarshish C.Y., Roche A., et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22 (2001) 529-539
20. Dixon R.M., Bradley K.M., Budge M.M., Styles P., and Smith A.D. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 125 (2002) 2332-2341
21. Fillenbaum G.G., and Smyer M.A. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol 36 (1981) 428-434
22. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
23. Fox N.C., Cousens S., Scahill R., Harvey R.J., and Rossor M.N. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 57 (2000) 339-344
24. Fox N.C., and Freeborough P.A. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging 7 (1997) 1069-1075
25. Fox N.C., Warrington E.K., Freeborough P.A., Hartikainen P., Kennedy A.M., Stevens J.M., et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 119 Pt 6 (1996) 2001-2007
26. Francis P.T., Nordberg A., and Arnold S.E. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. Trends Pharmacol Sci 26 (2005) 104-111
27. Frederick B., Satlin A., Wald L.L., Hennen J., Bodick N., and Renshaw P.F. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. Am J Geriatr Psychiatry 10 (2002) 81-88
28. Garwood M., and DelaBarre L. The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J Magn Reson 153 (2001) 155-177
29. 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility. J Magn Reson Imaging 20 (2004) 366-371
30. Grady C.L., Furey M.L., Pietrini P., Horwitz B., and Rapoport S.I. Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease. Brain 124 (2001) 739-756
31. 1H magnetic resonance spectroscopy study. Neurosci Lett 362 (2004) 167-170
32. Hashimoto M., Kazui H., Matsumoto K., Nakano Y., Yasuda M., and Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?. Am J Psychiatry 162 (2005) 676-682
33. Hattori N., Abe K., Sakoda S., and Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. NeuroReport 13 (2002) 183-186
34. Hsu Y.Y., Chen M.C., Lim K.E., and Chang C. Reproducibility of hippocampal single-voxel proton MR spectroscopy and chemical shift imaging. AJR Am J Roentgenol 176 (2001) 529-536
35. Isobe T., Matsumura A., Anno I., Yoshizawa T., Nagatomo Y., Itai Y., et al. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging 20 (2002) 343-349
36. Jessen F., Block W., Traber F., Keller E., Flacke S., Lamerichs R., et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 57 (2001) 930-932
37. Jessen F., Traeber F., Freymann K., Maier W., Schild H.H., and Block W. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67 (2006) 528-530
38. Jurica P.J., Leitten C.L., and Mattis S. Demential rating scale-2: professional manual. Psychological Assessment Resources: Lutz, Fl (2001)
39. 1H MR spectroscopy study at 4 T. Neurobiol Aging 26 (2005) 665-672
40. 1H magnetic resonance spectroscopy study at 4 Tesla. NMR Biomed 18 (2005) 51-55
41. 1H MRS study. Neurology 55 (2000) 210-217
42. 1H MR spectroscopy in common dementias. Neurology 63 (2004) 1393-1398
43. Kantarci K., Reynolds G., Petersen R.C., Boeve B.F., Knopman D.S., Edland S.D., et al. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am J Neuroradiol 24 (2003) 843-849
44. Kantarci K., Xu Y., Shiung M.M., O'Brien P.C., Cha R.H., Smith G.E., et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 14 (2002) 198-207
45. Kassem M.N., and Bartha R. Quantitative proton short-echo-time LASER spectroscopy of normal human white matter and hippocampus at 4 Tesla incorporating macromolecule subtraction. Magn Reson Med 49 (2003) 918-927
46. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 107 (2000) 1027-1063
47. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med 14 (1990) 26-30
48. Klunk W.E., Panchalingam K., Moossy J., McClure R.J., and Pettegrew J.W. N-acetyl-l-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology 42 (1992) 1578-1585
49. Knight-Scott J. Application of multiple inversion recovery for suppression of macromolecule resonances in short echo time (1)H NMR spectroscopy of human brain. J Magn Reson 140 (1999) 228-234
50. Krishnan K.R., Charles H.C., Doraiswamy P.M., Mintzer J., Weisler R., Yu X., et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160 (2003) 2003-2011
51. Lucas J.A., Ivnik R.J., Smith G.E., Bohac D.L., Tangalos E.G., Kokmen E., et al. Normative data for the Mattis Dementia Rating Scale. J Clin Exp Neuropsychol 20 (1998) 536-547
52. Marquardt D.W. An algorithm for least-squares estimations of nonlinear parameters. J Soc Indust Appl Math 11 (1963) 431-441
53. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
54. Miller B.L., Moats R.A., Shonk T., Ernst T., Woolley S., and Ross B.D. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 187 (1993) 433-437
55. Moats R.A., Ernst T., Shonk T.K., and Ross B.D. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 32 (1994) 110-115
56. Modrego P.J., Pina M.A., Fayed N., and Diaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs 20 (2006) 867-877
57. Nobili F., Vitali P., Canfora M., Girtler N., De Leo C., Mariani G., et al. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol 113 (2002) 1241-1248
58. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E.V., and Lim K.O. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med 41 (1999) 276-284
59. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 141 (1984) 1356-1364
60. Ross B.D. Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed 4 (1991) 59-63
61. Ross B.D., Bluml S., Cowan R., Danielsen E., Farrow N., and Tan J. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am 8 (1998) 809-822
62. Sasaki H., Muramoto O., Kanazawa I., Arai H., Kosaka K., and Iizuka R. Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type. Ann Neurol 19 (1986) 263-269
63. Schuff N., Amend D., Ezekiel F., Steinman S.K., Tanabe J., Norman D., et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 49 (1997) 1513-1521
64. Stokes C.E., and Hawthorne J.N. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J Neurochem 48 (1987) 1018-1021
65. Streit W.J. Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 77 (2004) 1-8
66. Sunderland T., Hill J.L., Mellow A.M., Lawlor B.A., Gundersheimer J., Newhouse P.A., et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 37 (1989) 725-729
67. Tkac I., Starcuk Z., Choi I.Y., and Gruetter R. In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 41 (1999) 649-656
68. Tkac I., Ugurbil K., and Gruetter R. On the quantification of low concentration metabolites by 1H NMR spectroscopy in the human brain at 7 Tesla. 10th Annual Meeting of the International Society of Magnetic Resonance in Medicine (2002) 528 Honalulu, Hawaii, USA
69. Tune L., Tiseo P.J., Ieni J., Perdomo C., Pratt R.D., Votaw J.R., et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 11 (2003) 169-177
70. van den Boogaart A., Ala-Korpela M., Jokisaari J., and Griffiths J.R. Time and frequency domain analysis of NMR data compared: an application to 1D 1H spectra of lipoproteins. Magn Reson Med 31 (1994) 347-358
71. Wright I.C., McGuire P.K., Poline J.B., Travere J.M., Murray R.M., Frith C.D., et al. A voxel-based method for the statistical analysis of gray and white matter density applied to schizophrenia. NeuroImage 2 (1995) 244-252